Summary: Thermo Fisher Scientific introduced a new mass spectrometer (MS) that is designed to enhance translational omics research by offering high throughput, sensitivity, and ease of use, thus facilitating faster and more efficient discovery and validation of biomarkers for clinical applications.

Takeaways:

  1. The Stellar MS integrates with the Orbitrap Astral MS to streamline the transition from basic scientific discoveries to clinical applications, enabling the verification of clinically significant proteins and metabolites.
  2. The system supports third-party software via the Thermo Scientific Ardia platform and features high throughput liquid chromatography, allowing researchers to create new workflows in days rather than weeks, significantly improving productivity.
  3. The Stellar MS offers ten times the quantitative sensitivity and can analyze five times more compounds compared to traditional technologies, accelerating the pace of precision medicine and the development of personalized therapies.

Thermo Fisher Scientific unveiled the Thermo Scientific Stellar mass spectrometer (MS), a new solution that combines fast throughput, high sensitivity, and ease of use to allow researchers to advance their translational omics research and make breakthrough discoveries more efficiently.

New Mass Spectrometer

The Stellar MS powers translational research, the conversion of basic science discoveries into clinical applications with the ultimate goal of improving human health, as it streamlines the verification of proteins and metabolites of clinical interest. Complementing the Thermo Scientific Orbitrap Astral MS, Stellar MS completes a key piece of the translational research workflow. The Orbitrap Astral MS is ideal for discovering new biomarkers and the Stellar MS connects these discoveries to clinical research, providing verification of all biomarkers that matter, including peptides, metabolites, and lipids.

Connectivity with Thermo Scientific Solutions

This workflow includes third-party software support via Thermo Scientific Ardia platform and high throughput liquid chromatography separation with the Thermo Scientific Vanquish Neo ultra-high performance liquid chromatography (UHPLC) system Tandem Direct Injection workflow, enabling significant time savings. Translational scientists can now create new workflows in just days rather than weeks using existing technology, ultimately delivering faster study completion that supports significantly improved productivity.

Compared to traditional technologies, Stellar MS achieves ten times the quantitative sensitivity while analyzing five times more compounds for proteomics, metabolomics, and lipidomics, the company says. Researchers can now achieve quantitative productivity and gain insights on a broader range of compounds which were previously impossible.

“Our industry-leading instruments will accelerate the promise of precision medicine and bolster essential translational research that will help improve human health,” says John Lesica, president, chromatography and mass spectrometry, Thermo Fisher Scientific. “Equipping our customers with the ability to discover and validate insights at unprecedented scale can offer biological insights into disease mechanisms that improve clinical research outcomes and help develop personalized therapies far faster than previously possible.”